Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, have revolutionized the treatment landscape for patients with diabetes and heart failure. This evidence concerns the gene SLC5A2 and heart failure.